



(51) International Patent Classification:

A61K 31/785 (2006.01) *C08F 226/04* (2006.01)
A61K 31/787 (2006.01) *C08F 8/00* (2006.01)
C08F 226/02 (2006.01)

(21) International Application Number:

PCT/US2015/066006

(22) International Filing Date:

16 December 2015 (16.12.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/093,751 18 December 2014 (18.12.2014) US

(71) Applicant: GENZYME CORPORATION [US/US]; 500
Kendall Street, Cambridge, Massachusetts 02142 (US).

(72) Inventors: **DHAL, Pradeep K.**; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-505A, Bridgewater, New Jersey 08807 (US). **MILLER, Robert J.**; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-505A, Bridgewater, New Jersey 08807 (US). **POLOMOSCANIK, Steven C.**; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-505A, Bridgewater, New Jersey 08807 (US). **LARSEN, Philip Just**; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **HUEBSCHLE, Thomas**; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **SCHMIDT, Thorsten**; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **DAVISON, Ian**; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-505A, Bridgewater, New Jersey 08807 (US). **MCDONNELL, Peter**; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-505A, Bridgewater, New Jersey 08807 (US). **AGBUGBA, Chinyere**; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-505A, Bridgewater, New Jersey 08807 (US).

(74) Agents: **ADAMS, Chandra K.** et al.; Sanofi U.S., 55 Corporate Drive, Mail Code: 55A - 505A, Bridgewater, New Jersey 08807 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

(54) Title: **CROSSLINKED POLYDIALLYLAMINE COPOLYMERS FOR THE TREATMENT OF TYPE 2 DIABETES**

(57) Abstract: Polydiallylamine copolymers are copolymers comprising monomers of polydiallylamine and either polyvinylamine or polyallylamine. Polydiallylamine copolymers are often crosslinked. The polydiallylamine copolymers are useful as pharmaceutical compositions and may be used in the treatment of type 2 diabetes and for mitigating the complications of type 2 diabetes.



WO 2016/100456 A2